Company news

Relmada Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

March 11, 2024

Relmada Therapeutics Provides Corporate Update

January 3, 2024

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 7, 2023

Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023

November 2, 2023

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

September 19, 2023

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

August 22, 2023

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 7, 2023

Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023

July 31, 2023

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 10, 2023

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

March 22, 2023

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023

March 16, 2023

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

January 11, 2023

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

January 8, 2023

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

December 6, 2022

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 9, 2022

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

October 12, 2022

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

September 19, 2022

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 10, 2022

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

August 8, 2022

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

August 4, 2022

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

July 20, 2022

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 4, 2022

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

April 28, 2022

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

April 27, 2022

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

March 22, 2022

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022

March 15, 2022

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

February 22, 2022

Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

December 21, 2021

Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

December 13, 2021

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

December 7, 2021

Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

December 7, 2021

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 10, 2021

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 9, 2021

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

July 26, 2021

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

July 19, 2021

Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting

May 25, 2021

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 11, 2021

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

May 5, 2021

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

April 30, 2021

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

April 28, 2021

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

April 27, 2021

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

April 26, 2021

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

March 31, 2021

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

March 22, 2021

Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

December 6, 2020

Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones

October 26, 2020

Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®

July 12, 2020

Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms

June 22, 2020

Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder

May 26, 2020

Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations

May 25, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 34 decks. Every deck is listed under its year.